Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT2 | O60551 | 1/20 | 0.46 |
| ▸ | NMT1 | P30419 | 1/20 | 0.46 |
| ▸ | TFPI | P10646 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.41 |
| ▸ | BACE1 | P56817 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6856783 | 1.00 | NMT2 (0.46) | NMT2NMT1TFPIGRIN2DGRIN3B | |
| SCHEMBL30720015 | 0.92 | TFPI (0.44) | NMT2NMT1TFPIGRIN2DGRIN3B | |
| SCHEMBL30882784 | 0.90 | NMT1 (0.49) | NMT2NMT1TFPITLR2OPRL1 | |
| SCHEMBL29769744 | 0.86 | NMT1 (0.54) | NMT2NMT1TFPIGRIN2DGRIN3B | |
| SCHEMBL10740541 | 0.85 | NMT1 (0.50) | NMT2NMT1TFPIGRIN2DGRIN3B | |
| SCHEMBL10740555 | 0.85 | NMT1 (0.50) | NMT2NMT1TFPIGRIN2DGRIN3B | |
| SCHEMBL30512616 | 0.85 | FOLH1 (0.47) | NMT2NMT1TFPIGRIN2DGRIN3B | |
| SCHEMBL30905707 | 0.85 | GRIN2D (0.46) | NMT2NMT1TFPIGRIN2DGRIN3B | |
| SCHEMBL31187471 | 0.84 | FOLH1 (0.58) | NMT2NMT1FOLH1BACE1 | |
| SCHEMBL29549411 | 0.84 | FOLH1 (0.58) | NMT2NMT1FOLH1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114945593-B | Anti-IL-1 beta antibodies | 伊莱利利公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-117412986-A | Viral vectors for cancer therapy | 克里斯托生物技术股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-116235054-A | Method for determining a subject's predisposition from a light-medium COVID-19 disease course to a severe or critical disease course | 赛欧米克斯股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230121387-A1 | METHODS AND COMPOSITIONS FOR TREATING MUSCLE ATROPHY | NellOne Therapeutics, Inc. (US) | 2023-04-20 | — | — | US | disclosed |
| CN-115916961-A | T cells | 约奥罗波安图内斯分子医学研究所 | 2023-04-04 | — | — | CN | disclosed |
| CN-115667523-A | Activatable cytokine constructs and related compositions and methods | 西托姆克斯治疗公司 | 2023-01-31 | — | — | CN | disclosed |
| EP-4114438-A1 | METHODS AND COMPOSITIONS FOR TREATING MUSCLE ATROPHY | Nellone Therapeutics Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| CN-114945593-A | anti-IL-1 beta antibodies | 伊莱利利公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-114728072-A | TGF-beta polypeptides | 库尔生物制药有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114277055-A | Non-human animal humanized by IL1B and IL1A genes and construction method and application thereof | 百奥赛图(北京)医药科技股份有限公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-0636179-B1 | OIL-BODY PROTEINS AS CARRIERS OF HIGH-VALUE PEPTIDES IN PLANTS | SEMBIOSYS GENETICS INC (CA) | 2004-09-22 | — | — | EP | disclosed |